We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Guerbet

Offers products in medical imaging - diagnostic imaging, contrast media - contrast agents, MRI imaging, X Ray imaging... read more Featured Products: More products

Download Mobile App




FDA Approves Contrast Agent for Pediatric Patients

By MedImaging International staff writers
Posted on 12 Sep 2017
The US Food and Drug Administration (FDA) has approved the MRI contrast agent gadoterate meglumine for intravenous use in children younger than two years old, as well as neonates.

The agent is used to visualize abnormal vascularity in the Central Nervous System (CNS), and a disrupted Blood Brain Barrier (BBB), and previously had FDA approval only for children older than two.

The agent Dotarem (gadoterate meglumine) is manufactured by Guerbet (Paris, France). Dotarem is an ionic gadolinium-based and macrocyclic contrast medium, and has been approved for use in 79 countries.

The review by the FDA was based on a study of 51 children aged 23 months and less, including neonates, in nine centers. The results of the study showed that the safety, and PharmacoKinetic (PK) profiles, using a standard dose (0.1 mmol/kg), were similar in the study group to those of adults and children more than two years old. The observed safety profile of Dotarem in the study group was consistent with that reported in older patients.

VP North America at Guerbet, Massimo Carrara, said, "It is critical for Guerbet to help patients and their healthcare providers meet this medical need. We are committed to providing safe and effective contrast media to improve diagnosis of all populations including those who need special care, like young children. In fact, a study published earlier this year in Pediatric Radiology found that 80% of children's hospitals surveyed now use macrocyclic contrast agents."

Radiation Safety Barrier
RayShield Intensi-Barrier
40/80-Slice CT System
uCT 528
Digital Radiographic System
OMNERA 300M
X-Ray Illuminator
X-Ray Viewbox Illuminators

Channels

Nuclear Medicine

view channel
Image: The new tracer, 64Cu-NOTA-EV-F(ab′)2​, targets nectin-4, a protein strongly linked to tumor growth in both TNBC and UBC cancer types. (Wenpeng Huang et al., DOI: 10.2967/jnumed.125.270132)

PET Tracer Enables Same-Day Imaging of Triple-Negative Breast and Urothelial Cancers

Triple-negative breast cancer (TNBC) and urothelial bladder carcinoma (UBC) are aggressive cancers often diagnosed at advanced stages, leaving limited time for effective treatment decisions.... Read more

General/Advanced Imaging

view channel
Image: Concept of the photo-thermoresponsive SCNPs (J F Thümmler et al., Commun Chem (2025). DOI: 10.1038/s42004-025-01518-x)

New Ultrasmall, Light-Sensitive Nanoparticles Could Serve as Contrast Agents

Medical imaging technologies face ongoing challenges in capturing accurate, detailed views of internal processes, especially in conditions like cancer, where tracking disease development and treatment... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.